4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.93
+0.47 (5.56%)
At close: Mar 4, 2026, 4:00 PM EST
8.88
-0.05 (-0.56%)
After-hours: Mar 4, 2026, 6:02 PM EST
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $90.00K in the quarter ending September 30, 2025, with 2,900.00% growth. This brings the company's revenue in the last twelve months to $120.00K, up 605.88% year-over-year. In the year 2024, 4D Molecular Therapeutics had annual revenue of $37.00K, down -99.82%.
Revenue (ttm)
$120.00K
Revenue Growth
+605.88%
P/S Ratio
3,795.84
Revenue / Employee
$529
Employees
227
Market Cap
455.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.00K | -20.69M | -99.82% |
| Dec 31, 2023 | 20.72M | 17.59M | 562.29% |
| Dec 31, 2022 | 3.13M | -14.91M | -82.65% |
| Dec 31, 2021 | 18.04M | 4.43M | 32.52% |
| Dec 31, 2020 | 13.61M | 6.63M | 94.85% |
| Dec 31, 2019 | 6.99M | -7.14M | -50.56% |
| Dec 31, 2018 | 14.13M | 8.34M | 144.04% |
| Dec 31, 2017 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 216.11M |
| REGENXBIO | 161.32M |
| Invivyd | 50.04M |
| Assembly Biosciences | 37.19M |
| Verastem | 13.38M |
| Lineage Cell Therapeutics | 10.82M |
FDMT News
- 13 days ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 23 days ago - 4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD - GlobeNewsWire
- 7 weeks ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - 4DMT Provides Company Update and Anticipated Development Milestones for 2026 - GlobeNewsWire
- 2 months ago - 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript - Seeking Alpha
- 2 months ago - 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - GlobeNewsWire
- 3 months ago - 4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire